摘要：目的 探讨利维爱联合盐酸米多君治疗绝经后女性尿失禁的有效性和可行性.方法 采用随机、双盲、安慰剂平行对照的方法对120例绝经期女性尿失禁患者进行利维爱联合盐酸米多君与安慰剂对照组的对比研究.试验组60例,利维爱2.5 mg/次,1次/d,同时加用盐酸米多君2.5 mg/次,3次/d,疗程3个月;对照组60例,给予安慰剂.均分别在给药4周和3个月时观察疗效.结果 120例均未失访,治疗组症状改善率达56.1%,恶化率达26.7%;对照组改善率达22.6%,恶化率达33.8%.治疗组症状改善率明显高于对照组,两组比较差异有统计学意义(uc≈59.9658,P＜0.01),但治疗时间的长短对疗效无明显影响(χ2≈0.6265,P＞0.05).结论 利维爱联合盐酸米多君可以改善绝经后女性尿失禁的症状,是治疗绝经后妇女尿失禁的一种有效方法. Abstract： Objective To investigate the efficacy and feasibility of liviral plus midodrine in postmenopause women with incontinence. Methods A randomized,double-blind,parallel,placebo-controlled study was carried out.One hundred and twenty postmenopause women with incontinence were involved in. Sixty cases in study group received liviral(2.5 mg/d) and midodrine (2.5 mg,thrice daily)for three months.Sixty cases in control group received placebo in the same way. Results One hundred and twenty cases completed the treatment. Incontinence improved in 22.6% of the women assigned to placebo compared with 56.1% assigned to liviral and midorine, while 33.8% of the placebo group worsened compared with 26.7% of the liviral and midorine group (P＜0.01). This difference was evident by 4 weeks of treatment,but there was no obvious greater improvement for three months of treatment (P＞0.05). Conclusions Liviral combined with midodrine hydrocholoride therapy is associated with improving urinary incontinence in older postmenopausal women with incontinence. We believe this therapy will be effective for the treatment of incontinence in postmenopause wome

注：因版权方要求，不能公开全文，如需全文，请咨询杂志社